# Emcure Pharmaceuticals Ltd (EMCURE)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1751.5
Day Change: +1.01%
52W High: ₹1830
52W Low: ₹1047
Market Cap: ₹31,864 Cr

## Valuation
P/E: 34.47
P/B: 6.44
EPS: ₹48.76
Book Value: ₹261.12
Dividend Yield: 0.21%

## Returns
1Y Return: 18.11%

## Profitability
ROE: 19.57%
ROCE: 21.68%
Debt/Equity: 0.31
Revenue Growth: 16.7%
Profit Growth: 28.8%
EBITDA Margin: 19.43%
Operating Margin: 15.35%

## About
Emcure Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Emcure Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand, Ahmedabad, Gujarat, India.
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- BSE Filing: Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand, Ahmedabad, Gujarat, India.

## Access
Current tier: anonymous
More history: Register free to see 4 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:01.518Z
Price History Updated: 2026-05-18T22:58:12.821Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:12.821Z
Quant Updated: 2026-05-18T22:58:12.821Z
Sentiment Updated: 2026-05-18T22:58:12.821Z
Financials Status: current
Financials Updated: 2026-05-18T08:30:31.065Z
Financials Last Attempt: 2026-05-18T08:30:31.065Z
Financials Provider Tried: yahoo
Latest P&L Period: FY26
Latest Balance Sheet Period: FY26
Latest Cash Flow Period: FY26

## P&L (Mar 2020)
Revenue: ₹4717 Cr
Operating Profit: ₹749 Cr (OPM 16%)
Net Profit: ₹209 Cr
Tax: ₹331 Cr

## Annual P&L History
Mar 2020: Rev ₹4717Cr | PAT ₹209Cr | OPM 16%
Mar 2021: Rev ₹5049Cr | PAT ₹101Cr | OPM 14%
Mar 2022: Rev ₹5033Cr | PAT ₹419Cr | OPM 24%

## Balance Sheet (Mar 2020)
Total Assets: ₹5577 Cr
Total Liabilities: ₹5577 Cr
Borrowings: ₹2128 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Satish Ramanlal Mehta, CEO, MD & Executive Director
- Samit Satish Mehta, President of Operations & Whole-Time Director
- Mukund Keshao Gurjar, Chief Scientific Officer & Whole-Time Director
- Sunil Rajanikant Mehta, Executive Director of Projects & Whole-Time Director
- Namita Vikas Thapar, Executive Director of India Business & Whole-Time Director

---
Source: rupiya.io/stocks/emcure
Disclaimer: For research and education only. Not investment advice.